Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
B

Protocol

Polypill (statin and blood pressure drugs in one daily pill)

In SECURE, 2,499 people after a heart attack given a polypill (aspirin, ramipril and atorvastatin) had fewer cardiovascular events than with usual care (9.5% against 12.7%, HR 0.76).

Compare this record with another, side by side →

At a glance

In plain words

A polypill puts several heart drugs into one daily pill. It usually has a statin, blood pressure drugs and sometimes aspirin. After a heart attack, people on the polypill had fewer new heart problems than people on their usual pills. In people without heart disease it also helped, but that result was right on the edge.

The letter, taken apart
What was measured
Heart attacks, strokes, heart-related deaths and urgent heart procedures.
How big
After a heart attack, new heart problems were 9.5% with the polypill against 12.7% with usual care.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 36018037.
Who it applies to
Adults after a heart attack, and adults at intermediate risk without heart disease.
Safety
The aspirin component raises bleeding risk; pill-specific doses were used in the trials.
The record in one view
Compared with
Usual separate medicines (SECURE) or placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. (TIPS-3).
Certainty
Grade B, resting on: Two large randomized trials with hard cardiovascular endpoints The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score., in different populations.
What would change this grade
Could rise to A with: Randomized trial of a polypill. Who: Adults without heart disease at intermediate risk, a second population. Measured: Major cardiovascular events. Length: At least 4 years.
Cost
No price recorded yet.
Sources
2 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
BHard clinical endpoint Grade B

In SECURE, 2,499 people after a heart attack given a polypill (aspirin, ramipril and atorvastatin) had fewer cardiovascular events than with usual care (9.5% against 12.7%, HR 0.76). In TIPS-3, 5,713 people without heart disease given a polypill had fewer events than with placebo (4.4% against 5.5%, HR 0.79), with a confidence interval The range the true effect probably falls in. A wide interval means the estimate is uncertain. that reached no effect. The two trials tested different people, so neither replicates the other.

Why this letter

Why this gradeThe reasoning, and what the grade does not cover.
Why this grade

Grade B on major cardiovascular events. After a heart attack, a polypill lowered events against usual care (Castellano et al., 2022; PMID 36018037), and in people without heart disease it lowered events against placebo with an interval reaching no effect (Yusuf et al., 2021; PMID 33186492). SUPPORT: SECURE's result is supported by TIPS-3, an independent trial by a different group in a different population, whose result points the same way.

WHY NOT Athe two trials tested different populations and comparators, so neither replicates the other, and the primary-prevention result is borderline.

WHAT THIS GRADE DOES NOT COVERthe separate drugs taken as separate pills, which are graded on the statin and blood pressure records, and aspirin for primary prevention in healthy older adults, which has its own record and a different answer.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial

Endpoint graded: Major cardiovascular events (hard)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of a polypill
PopulationAdults without heart disease at intermediate risk, a second population
EndpointMajor cardiovascular events
DurationAt least 4 years

Positive trials of this shape from independent research groups would move this entry to A.

Why the current trials fall short

A second primary-prevention trial would supply replication The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away..

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Drug Combinations among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Drug Combinations on ClinicalTrials.gov

Dose, form and timing

What to track

Blood pressure, LDL Low-density lipoprotein cholesterol, the cholesterol fraction most closely tied to plaque in the arteries. cholesterol, and bleeding if aspirin is part of the pill.

As studiedDose, form, population and duration for every use.
As studied
FormPolypill of aspirin 100 mg, ramipril and atorvastatin (SECURE, PMID 36018037); polypill of simvastatin, atenolol, hydrochlorothiazide and ramipril with or without aspirin (TIPS-3, PMID 33186492).
DoseOne pill daily; aspirin 100 mg in SECURE (PMID 36018037), 75 mg in TIPS-3 (PMID 33186492).
PopulationAdults within 6 months of a heart attack (PMID 36018037); adults at intermediate risk without heart disease (PMID 33186492).
DurationMedian 36 months (PMID 36018037); mean 4.6 years (PMID 33186492).

A grade describes the intervention that was tested. Where the product on the shelf differs from it, this says so.

Safety

Safety evidence, by strength

No human harm data, with cautions for groups never studied. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.
  • People who bleed easily or take other blood thinners: the aspirin component adds bleeding risk
No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 462 · November 2026 · First graded.
Grade history
No. 462 · November 2026 · First graded
Polypill (statin and blood pressure drugs in one daily pill) is added from the gap report: Grade B

New record in the gap-report batch. In SECURE, 2,499 people after a heart attack given a polypill (aspirin, ramipril and atorvastatin) had fewer cardiovascular events than with usual care (9.5% against 12.7%, HR 0.76). In TIPS-3, 5,713 people without heart disease given a polypill had fewer events than with placebo (4.4% against 5.5%, HR 0.79), with a confidence interval that reached no effect. The two trials tested different people, so neither replicates the other.PMID 36018037 PMID 33186492

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullTwo papers, each linked to its PubMed record.
The evidence

Castellano et al. (N Engl J Med, 2022; PMID 36018037): SECURE, 2,499 patients within 6 months of myocardial infarction, polypill against usual care, median 36 months; primary outcome 9.5% against 12.7% (HR 0.76, 95% CI 0.60 to 0.96). Yusuf et al. (N Engl J Med, 2021; PMID 33186492): TIPS-3, 5,713 people at intermediate risk without cardiovascular disease, polypill against placebo, mean 4.6 years; LDL about 19 mg/dL and systolic pressure about 5.8 mmHg lower; primary outcome 4.4% against 5.5% (HR 0.79, 95% CI 0.63 to 1.00).

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 8 records screened, 2 eligible for the graded claim.
Query: (polypill[tiab] OR "fixed-dose combination"[tiab]) AND cardiovascular[tiab] AND randomized controlled trial[pt]
The 8 most recent of 111 records were screened by title; they concern other fixed-dose combinations, not cardiovascular polypills. SECURE (PMID 36018037) and TIPS-3 (PMID 33186492) are on the record.
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Castellano et al., 2022, N Engl J Med (PMID 36018037): PubMed lists funding from European Union Horizon 2020.
  • Yusuf et al., 2021, N Engl J Med (PMID 33186492): PubMed lists funding from Wellcome Trust and others; Wellcome Trust; Wellcome; CIHR.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026